Mathematical modelling of prostate cancer growth and its application to hormone therapy

Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences

Volumn 368, Issue 1930, 2010, Pages 5029-5044

  Tanaka, Gouhei ^a   Hirata, Yoshito ^a   Goldenberg, S Larry ^b   Bruchovsky, Nicholas ^b   Aihara, Kazuyuki ^b  

^a INSTITUTE OF INDUSTRIAL SCIENCE   (Japan)

^b VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

Cprostate cancer; Hybrid dynamical systems; Intermittent hormone therapy; Prostate specific antigen; Stochastic differential equations; Time series analysis

Indexed keywords

ANTIGENS; BODY FLUIDS; DIFFERENTIAL EQUATIONS; DISEASE CONTROL; DYNAMICAL SYSTEMS; HARMONIC ANALYSIS; MEASUREMENT THEORY; POSITION CONTROL; ROBUSTNESS (CONTROL SYSTEMS); STOCHASTIC MODELS; STOCHASTIC SYSTEMS; TIME SERIES ANALYSIS; TUMORS;

CPROSTATE CANCER; HYBRID DYNAMICAL SYSTEMS; INTERMITTENT HORMONE THERAPY; PROSTATE SPECIFIC ANTIGEN; STOCHASTIC DIFFERENTIAL EQUATIONS;

DISEASES;

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROSTATE SPECIFIC ANTIGEN;

BIOLOGICAL MODEL; BLOOD; CELL GROWTH; COMPUTER SIMULATION; DRUG EFFECT; HUMAN; MALE; NEOPLASM; NONLINEAR SYSTEM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVIEW; STATISTICS;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL GROWTH PROCESSES; COMPUTER SIMULATION; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; NONLINEAR DYNAMICS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STOCHASTIC PROCESSES;

EID: 78649369807     PISSN: 1364503X     EISSN: None     Source Type: Journal    
DOI: 10.1098/rsta.2010.0221     Document Type: Article

References (44)

1. Abrahamsson, P.-A. 2010 Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur. Urol. 57, 49-59. (doi:10.1016/j.eururo.2009.07.049)
2. Akakura, K., Bruchovsky, N., Goldenberg, S. L., Rennie, P. S., Buckley, A. R. & Sullivan, L. D. 1993 Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 71, 2782-2790. (doi:10.1002/1097-0142(19930501)71:9<2782::AID- CNCR2820710916>3.0.CO;2-Z)
3. Berges, R. R., Vukanovic, J., Epstein, J. I., CarMichel, M., Cisek, L., Johnson, D. E., Veltri, R. W., Walsh, P. C. & Isaacs, J. T. 1995 Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. 1, 473-480.
4. Bhandari, M. S., Crook, J. & Hussain, M. 2005 Should intermittent androgen deprivation be used in routine clinical practice? J. Clin. Oncol. 23, 8212-8218. (doi:10.1200/JCO.2005.03.2557) (Pubitemid 46211557)
5. Bladou, F., Vessella, R. L., Buhler, K. R., Ellis, W. J., True, L. D. & Lange, P. H. 1996 Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int. J. Cancer 67, 785-790. (doi:10.1002/(SICI)1097-0215(19960917) 67:6<785::AID-IJC6>3.0.CO;2-N)
6. Brawer, M. K. 2006 Hormonal therapy for prostate cancer. Rev. Urol. 8(Suppl. 2), S35-S47.
7. Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., To, M. & Lawson, D. 1990 Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 50, 2275-2282.
8. Bruchovsky, N., Klotz, L. H., Sadar, M., Crook, J. M., Hoffart, D., Godwin, L., Warkentin, M., Gleave, M. E. & Goldenberg, S. L. 2000 Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol. Urol. 4, 191-199.
9. Bruchovsky, N., Goldenberg, S. L., Mawji, N. R. & Sadar, M. D. 2001 Evolving aspects of intermittent androgen blockade for prostate cancer: diagnosis and treatment of early tumor progression and maintenance of remission. In Proc. 7th Int. Congress of Andrology, Montreal, Canada, 15-19 June 2001 (eds B. Robaire, H. Chemes & C. R. Morales), pp. 609-623. Bologna, Italy: Medimond.
10. Bruchovsky, N., Klotz, L., Crook, J., Malone, S., Ludgte, C., Morris, W. J., Gleave, M. E. & Goldenberg, S. L. 2006 Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer 107, 389-395. (doi:10.1002/cncr.21989) (Pubitemid 44036569)
11. Bruchovsky, N., Klotz, L., Crook, J., Larry, S. & Goldenberg, S. L. 2007 Locally advanced prostate cancer - biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 109, 858-867. (doi:10.1002/cncr.22464) (Pubitemid 46333527)
12. Chodak, G. W. 2005 Maximum androgen blockade: a clinical update. Rev. Urol. 7(Suppl. 5), S13-S17.
13. Chuu, C.-P., Hiipakka, R. A., Fukuchi, J., Kokontis, J. M. & Liao, S. 2005 Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 65, 2082-2084. (doi:10.1158/0008-5472.CAN-04-3992) (Pubitemid 40490112)
14. Dehm, S. M. & Tindall, D. J. 2005 Regulation of androgen receptor signaling in prostate cancer. Expert Rev. Anticancer Ther. 5, 63-74. (doi:10.1586/14737140.5.1.63) (Pubitemid 40287437)
15. Edwards, J. & Bartlett, J. M. S. 2005 The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part I: modifications to the androgen receptor. BJU Int. 95, 1320-1326. (doi:10.1111/j.1464-410X.2005.05526.x) (Pubitemid 40799454)
16. Feldman, B. J. & Feldman, D. 2001 The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45. (doi:10.1038/35094009)
17. Gleave, M. 1998 Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostate Dis. 1, 289-296. (doi:10.1038/sj.pcan.4500260) (Pubitemid 128545877)
18. Goldenberg, S. L., Bruchovsky, N. & Gleave, M. E. 1995 Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45, 839-845. (doi:10.1016/S0090-4295(99)80092-2)
19. Guo, Q., Tao, Y. & Aihara, K. 2008 Mathematical modeling of prostate tumor growth under intermittent androgen suppression with partial differential equations. Int. J. Bifurcat. Chaos 18, 3789-3797. (doi:10.1142/ S0218127408022743)
20. Hirata, Y., Bruchovsky, N. & Aihara, K. 2010 Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. J. Theor. Biol. 264, 517-527. (doi:10.1016/j.jtbi.2010.02.027)
21. Huggins, C. & Hodges, C. V. 1941 Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293-297.
22. Hurtado-Coll, A., Goldenberg, S. L. & Gleave, M. E. 2002 Intermittent androgen suppression in prostate cancer: the Canadian experience. Urology 60(Suppl. 1), 52-56. (doi:10.1016/S0090-4295(02)01572-8) (Pubitemid 35304542)
23. Ideta, A. M., Tanaka, G., Takeuchi, T. & Aihara, K. 2008 A mathematical model of intermittent androgen suppression for prostate cancer. J. Nonlinear Sci. 18, 593-614. (doi:10.1007/s00332-008-9031-0)
24. Jackson, T. L. 2004a A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data. Neoplasia 6, 697-704. (doi:10.1593/neo.04259) (Pubitemid 40041487)
25. Jackson, T. L. 2004b A mathematical model of prostate tumor growth and androgen-independent relapse. Disc. Cont. Dyn. Syst. B 4, 187-201.
26. Kloeden, P. E. & Platen, E. 1992 Numerical solution of stochastic differential equations. Berlin, Germany: Springer.
27. Kokontis, J. M., Takakura, K., Hay, N. & Liao, S. 1994 Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 54, 1566-1573.
28. Kokontis, J. M., Hay, N. & Liao, S. 1998 Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol. Endocrinol. 12, 941-953. (doi:10.1210/me.12.7.941)
29. Kokontis, J. M., Hsu, S., Chuu, C.-p., Dang, M., Fukuchi, J., Hiipakka, R. A. & Liao, S. 2005 Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 65, 287-298. (doi:10.1002/pros.20285) (Pubitemid 41759960)
30. Ochiai, A., Troncoso, P. & Babaian, R. J. 2007 The relationship between serum prostate specific antigen level and tumor volume persists in the current era. J. Urol. 177, 903-906. (doi:10.1016/j.juro.2006.10.072) (Pubitemid 46216339)
31. Pether, M. & Goldenberg, S. L. 2004 Intermittent androgen suppression. BJU Int. 93, 258-261. (doi:10.1111/j.1464-410X.2004.04597.x) (Pubitemid 38253565)
32. Price, K. V., Storn, R. M. & Lampinen, J. A. 2005 Differential evolution: a practical approach to global optimization. Berlin, Germany: Springer.
33. Rao, A. R., Motiwala, H. G. & Karim, O. M. A. 2008 The discovery of prostate-specific antigen. BJU Int. 101, 5-10. (doi:10.1111/j.1464-410X.2007. 07138.x) (Pubitemid 350233553)
34. Rashid, M. H. & Chaudhary, U. B. 2004 Intermittent androgen deprivation therapy for prostate cancer. Oncologist 9, 295-301. (doi:10.1634/theoncologist.9-3-295) (Pubitemid 38756877)
35. Rennie, P. S., Bruchovsky, N. & Coldman, A. J. 1990 Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J. Steroid Biochem. Mol. Biol. 37, 843-847. (doi:10.1016/0960-0760(90)90430-S)
36. Rennie, P., Read, J. & Murphy, L. 2005 Hormones and cancer. In The basic science of oncology (eds I. F. Tannock, R. P. Hill, R. G. Bristow & L. Harrington), pp. 400-430. New York, NY: McGraw-Hill.
37. Sato, N., Gleave, M. E., Bruchovsky, N., Rennie, P. S., Goldenberg, S. L., Lange, P. H. & Sullivan, L. D. 1996 Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J. Steroid Biochem. Mol. Biol. 58, 139-146. (doi:10.1016/0960-0760(96)00018-0) (Pubitemid 26284510)
38. Scher, H. I., Buchanan, G., Gerald, W., Butler, L. M. & Tilley, W. D. 2004 Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr. Relat. Cancer 11, 459-476. (doi:10.1677/erc.1.00525) (Pubitemid 39331277)
39. Shaw, G. L., Wilson, P., Cuzick, J., Prowse, D. M., Goldenberg, S. L., Spry, N. A. & Oliver, T. 2007 International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int. 99, 1056-1065. (doi:10.1111/j.1464- 410X.2007.06770.x) (Pubitemid 46587917)
40. Shimada, T. & Aihara, K. 2008 A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer. Math. Biosci. 214, 134-139. (doi:10.1016/j.mbs.2008.03.001)
41. Suzuki, T., Bruchovsky, N. & Aihara, K. 2010 Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer. Phil. Trans. R. Soc. A 368, 5045-5059. (doi:10.1098/rsta.2010.0220)
42. Tanaka, G., Tsumoto, K., Tsuji, S. & Aihara, K. 2008 Bifurcation analysis on a hybrid systems model of intermittent hormonal therapy for prostate cancer. Physica D 237, 2616-2627. (doi:10.1016/j.physd.2008.03.044)
43. Tanaka, G., Tsuji, S. & Aihara, K. 2009 Grazing-induced crises in hybrid dynamical systems. Phys. Lett. A 373, 3134-3139. (doi:10.1016/j.physleta. 2009.06.060)
44. Tao, Y., Guo, Q. & Aihara, K. 2009 A model at the macroscopic scale of prostate tumor growth under intermittent androgen suppression. Math. Mod. Meth. Appl. Sci. 19, 2177-2201. (doi:10.1142/S021820250900408X)